Dual-Small-Molecule ADC Linker Design for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in expanding their therapeutic index with greater efficacy and less toxicity, particularly when combined with chemotherapeutic drugs, due to the short half-lives of these drugs, necessitating frequent administration and increased toxicity.
Innovation Solution
Development of an antibody-drug conjugate (ADC) with chemically linked functional small molecules that enhance the half-life of the conjugated molecules, incorporating cytotoxic agents and linkers with specific structures to improve targeted treatment of cancers and refractory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic drugs are combined with ADCs to expand treatment applications, then efficacy is improved, but toxicity increases due to short half-lives requiring frequent administration
Solution Approach 1:
The patent combines chemotherapeutic drugs with ADCs through covalent linkage to form a unified conjugate molecule. This merging allows the ADC component to provide long circulation half-life and targeted delivery, while the chemotherapeutic drug component provides potent cytotoxic activity, achieving synergistic efficacy without the frequent administration required when drugs are given separately
Solution Approach 2:
The patent uses a linker molecule as an intermediary to covalently connect the chemotherapeutic drug to the ADC. This linker serves as a mediator that maintains the stability of the conjugate during circulation while enabling controlled release of the drug at the target site, thereby reducing systemic toxicity while maintaining efficacy
2Reliability
If chemotherapeutic drugs are administered frequently to maintain effective concentration, then treatment efficacy is maintained, but patient toxicity increases
Solution Approach 1:
By merging the chemotherapeutic drug with the long-half-life ADC through covalent bonding, the conjugate inherits the prolonged circulation half-life of the ADC component. This eliminates the need for frequent re-administration while maintaining effective drug concentrations at the target site over extended periods, thereby reducing cumulative toxicity
Solution Approach 2:
The patent employs a linker designed with partial stability characteristics - stable enough to prevent premature drug release during circulation (avoiding toxicity), but labile enough to allow complete drug release at the target site (ensuring efficacy). This balanced approach achieves effective treatment with reduced toxic side effects
Data Source
AI summary
The present invention relates to an antibody-drug conjugate containing two or more functional small molecules for enhancement of targeted treatment of cancers and refractory diseases. The invention also relates to preparation of such conjugate, pharmaceutical compositions, and methods in treatment of cancers and refractory diseases.